Status:
COMPLETED
Pulmonary Artery Pressure in COVID-19 Survivors
Lead Sponsor:
Mansoura University Hospital
Conditions:
Pulmonary Hypertension Secondary
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Post COVID-19 pulmonary hypertension can develop as a result of lung parenchymal damage and altered pulmonary circulation induced by COVID-19 infection. It has been proposed that this type of PH shoul...
Detailed Description
Coronavirus disease 2019 (COVID-19), the highly contagious viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a catastrophic effect on the world's demographi...
Eligibility Criteria
Inclusion
- COVID-19 survivors from a moderate/severe COVID-19 pulmonary infection according to WHO COVID-19 clinical severity classification , ≥ 18 years, with residual symptoms and signs suggestive of pulmonary hypertension and not explained by other condition.
Exclusion
- Previous diseases that could explain the existence of PH e.g. cardiovascular, pulmonary diseases or history of pulmonary thromboembolism.
- Hemodynamic instability.
- Absolute contraindications to RHC placement include:
- Infection at the insertion site.
- The presence of a right ventricular assist device.
- Insertion during cardiopulmonary bypass.
- Lack of consent.
- Relative contraindications to RHC placement include:
- Coagulopathy (INR \>1.5), thrombocytopenia (platelet count \<50,000/microL).
- Electrolyte disturbances.
- Severe acid-base disturbances.
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2024
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05993338
Start Date
April 1 2022
End Date
March 1 2024
Last Update
June 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
faculty of medicine Mansoura university
Al Mansurah, Egypt